Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram

Pharmacotherapy

Volumn 21, Issue 2, 2001, Pages 163-168

  Gutierrez, M ^a   Abramowitz, W ^a  

^a FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 3A4; KETOCONAZOLE; NORCITALOPRAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN;

ADULT; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CITALOPRAM; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; KETOCONAZOLE; LINEAR MODELS; MALE; MIXED FUNCTION OXYGENASES; SEROTONIN UPTAKE INHIBITORS;

EID: 0035146686     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.2.163.34101     Document Type: Article

References (23)

1. Citalopram and fluoxetine in major depression - Comparison of two clinical trials in a psychiatrist setting and in general practice
2. Multicenter, placebo-controlled, fixed dose study of citalopram in moderate to severe depression
3. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia
4. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression
5. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: A placebo-controlled 6 month study
6. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study
7. A comparison of the antidepressant action of citalopram and amitriptyline
8. Citalopram and anxiety disorders
9. Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression
10. The pharmacokinetics of citalopram
11. Identification of cytochrome p450 isoforms involved in citalopram Ndemethylation by human liver microsomes
12. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms
13. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects
14. Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions
15. Systemic antifungal agents. Drug interactions of clinical significance
16. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
17. Medication use in seniors: Challenges and solutions
18. Update: Clinically significant cytochrome P-450 drug interactions
19. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology
20. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes
21. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans
22. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects
23. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions